Yigal Nochomovitz
Stock Analyst at Citigroup
(3.40)
# 1,059
Out of 4,412 analysts
181
Total ratings
41.24%
Success rate
4.83%
Average return
Main Sectors:
Top Industries:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $88 → $89 | $53.91 | +65.09% | 16 | Apr 18, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Neutral | $1.8 → $2 | $1.94 | +3.09% | 2 | Apr 18, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Buy | $34 | $15.72 | +116.28% | 1 | Apr 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $40 → $60 | $39.94 | +50.23% | 2 | Mar 21, 2024 | |
| MGNX MacroGenics | Maintains: Buy | $13 → $25 | $14.56 | +71.70% | 9 | Mar 11, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Buy | $3 → $4 | $1.10 | +263.64% | 4 | Mar 7, 2024 | |
| ZLAB Zai Lab | Maintains: Buy | $123 → $66 | $15.91 | +314.83% | 7 | Feb 29, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $160 → $195 | $156.88 | +24.30% | 1 | Feb 27, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $30 | $15.44 | +94.30% | 1 | Feb 20, 2024 | |
| APLT Applied Therapeutics | Maintains: Buy | $5 → $7 | $4.28 | +63.55% | 4 | Feb 16, 2024 | |
| ARVN Arvinas | Downgrades: Neutral | $36 → $55 | $32.37 | +69.91% | 7 | Feb 15, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $40 → $48 | $26.55 | +80.79% | 5 | Feb 8, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $9.95 | +101.01% | 1 | Jan 30, 2024 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $14 | $6.42 | +118.07% | 6 | Jan 10, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $70 → $67 | $49.86 | +34.38% | 10 | Dec 15, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $90 | $10.78 | +734.88% | 6 | Dec 8, 2023 | |
| BGNE BeiGene | Maintains: Buy | $290 → $285 | $153.58 | +85.57% | 3 | Oct 26, 2023 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $25 → $8 | $3.93 | +103.56% | 8 | Oct 17, 2023 | |
| GRTX Galera Therapeutics | Maintains: Neutral | $0.4 → $0.25 | $0.19 | +34.34% | 2 | Aug 29, 2023 | |
| RCUS Arcus Biosciences | Maintains: Buy | $41 → $44 | $15.55 | +182.96% | 6 | Aug 24, 2023 | |
| ATRA Atara Biotherapeutics | Maintains: Sell | $2 → $1.4 | $0.69 | +102.90% | 7 | Aug 21, 2023 | |
| MRUS Merus | Maintains: Buy | $48 → $46 | $45.04 | +2.13% | 12 | Aug 10, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $31 → $35 | $21.06 | +66.19% | 4 | Jul 26, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $130 → $133 | $44.24 | +200.63% | 10 | Jun 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Maintains: Buy | $6 → $8 | $1.58 | +406.33% | 5 | May 31, 2023 | |
| UBX Unity Biotechnology | Maintains: Buy | $5 → $6 | $1.50 | +300.00% | 6 | May 26, 2023 | |
| ZYME Zymeworks | Maintains: Buy | $17 → $18 | $8.26 | +117.92% | 8 | May 18, 2023 | |
| ORIC ORIC Pharmaceuticals | Maintains: Buy | $9 → $8 | $8.07 | -0.87% | 4 | Apr 5, 2023 | |
| CLLS Cellectis | Maintains: Buy | $24 → $16 | $2.51 | +538.57% | 2 | Apr 5, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $9 → $10 | $3.80 | +163.16% | 3 | Mar 2, 2023 | |
| CALT Calliditas Therapeutics AB (publ) | Maintains: Buy | $76 → $79 | $19.50 | +305.12% | 1 | Feb 24, 2023 | |
| PROK ProKidney | Initiates: Buy | $16 | $2.12 | +654.72% | 1 | Oct 14, 2022 | |
| OPT Opthea | Maintains: Buy | $45 → $44 | $3.40 | +1,194.12% | 2 | Sep 16, 2022 | |
| IPHA Innate Pharma | Maintains: Buy | $16 → $12 | $2.46 | +387.80% | 1 | Sep 16, 2022 | |
| OVID Ovid Therapeutics | Maintains: Neutral | $2.4 → $2.5 | $3.10 | -19.35% | 4 | Aug 29, 2022 | |
| CRBU Caribou Biosciences | Maintains: Buy | $39 → $38 | $3.71 | +924.26% | 4 | Aug 29, 2022 | |
| STTK Shattuck Labs | Initiates: Buy | $13 | $10.59 | +22.76% | 1 | Jun 1, 2022 | |
| PBYI Puma Biotechnology | Maintains: Buy | n/a | $5.02 | - | 5 | Mar 1, 2019 |
CRISPR Therapeutics AG
Apr 18, 2024
Maintains: Buy
Price Target: $88 → $89
Current: $53.91
Upside: +65.09%
ProQR Therapeutics
Apr 18, 2024
Maintains: Neutral
Price Target: $1.8 → $2
Current: $1.94
Upside: +3.09%
LENZ Therapeutics
Apr 10, 2024
Initiates: Buy
Price Target: $34
Current: $15.72
Upside: +116.28%
IDEAYA Biosciences
Mar 21, 2024
Maintains: Buy
Price Target: $40 → $60
Current: $39.94
Upside: +50.23%
MacroGenics
Mar 11, 2024
Maintains: Buy
Price Target: $13 → $25
Current: $14.56
Upside: +71.70%
Rigel Pharmaceuticals
Mar 7, 2024
Maintains: Buy
Price Target: $3 → $4
Current: $1.10
Upside: +263.64%
Zai Lab
Feb 29, 2024
Maintains: Buy
Price Target: $123 → $66
Current: $15.91
Upside: +314.83%
Krystal Biotech
Feb 27, 2024
Maintains: Buy
Price Target: $160 → $195
Current: $156.88
Upside: +24.30%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $30
Current: $15.44
Upside: +94.30%
Applied Therapeutics
Feb 16, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.28
Upside: +63.55%
Arvinas
Feb 15, 2024
Downgrades: Neutral
Price Target: $36 → $55
Current: $32.37
Upside: +69.91%
Arcturus Therapeutics Holdings
Feb 8, 2024
Maintains: Buy
Price Target: $40 → $48
Current: $26.55
Upside: +80.79%
Olema Pharmaceuticals
Jan 30, 2024
Initiates: Buy
Price Target: $20
Current: $9.95
Upside: +101.01%
Ardelyx
Jan 10, 2024
Maintains: Buy
Price Target: $9 → $14
Current: $6.42
Upside: +118.07%
Apellis Pharmaceuticals
Dec 15, 2023
Maintains: Buy
Price Target: $70 → $67
Current: $49.86
Upside: +34.38%
Biomea Fusion
Dec 8, 2023
Reiterates: Buy
Price Target: $90
Current: $10.78
Upside: +734.88%
BeiGene
Oct 26, 2023
Maintains: Buy
Price Target: $290 → $285
Current: $153.58
Upside: +85.57%
Aldeyra Therapeutics
Oct 17, 2023
Maintains: Buy
Price Target: $25 → $8
Current: $3.93
Upside: +103.56%
Galera Therapeutics
Aug 29, 2023
Maintains: Neutral
Price Target: $0.4 → $0.25
Current: $0.19
Upside: +34.34%
Arcus Biosciences
Aug 24, 2023
Maintains: Buy
Price Target: $41 → $44
Current: $15.55
Upside: +182.96%
Atara Biotherapeutics
Aug 21, 2023
Maintains: Sell
Price Target: $2 → $1.4
Current: $0.69
Upside: +102.90%
Merus
Aug 10, 2023
Maintains: Buy
Price Target: $48 → $46
Current: $45.04
Upside: +2.13%
Syndax Pharmaceuticals
Jul 26, 2023
Maintains: Buy
Price Target: $31 → $35
Current: $21.06
Upside: +66.19%
Ultragenyx Pharmaceutical
Jun 7, 2023
Maintains: Buy
Price Target: $130 → $133
Current: $44.24
Upside: +200.63%
Lexicon Pharmaceuticals
May 31, 2023
Maintains: Buy
Price Target: $6 → $8
Current: $1.58
Upside: +406.33%
Unity Biotechnology
May 26, 2023
Maintains: Buy
Price Target: $5 → $6
Current: $1.50
Upside: +300.00%
Zymeworks
May 18, 2023
Maintains: Buy
Price Target: $17 → $18
Current: $8.26
Upside: +117.92%
ORIC Pharmaceuticals
Apr 5, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $8.07
Upside: -0.87%
Cellectis
Apr 5, 2023
Maintains: Buy
Price Target: $24 → $16
Current: $2.51
Upside: +538.57%
Fate Therapeutics
Mar 2, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $3.80
Upside: +163.16%
Calliditas Therapeutics AB (publ)
Feb 24, 2023
Maintains: Buy
Price Target: $76 → $79
Current: $19.50
Upside: +305.12%
ProKidney
Oct 14, 2022
Initiates: Buy
Price Target: $16
Current: $2.12
Upside: +654.72%
Opthea
Sep 16, 2022
Maintains: Buy
Price Target: $45 → $44
Current: $3.40
Upside: +1,194.12%
Innate Pharma
Sep 16, 2022
Maintains: Buy
Price Target: $16 → $12
Current: $2.46
Upside: +387.80%
Ovid Therapeutics
Aug 29, 2022
Maintains: Neutral
Price Target: $2.4 → $2.5
Current: $3.10
Upside: -19.35%
Caribou Biosciences
Aug 29, 2022
Maintains: Buy
Price Target: $39 → $38
Current: $3.71
Upside: +924.26%
Shattuck Labs
Jun 1, 2022
Initiates: Buy
Price Target: $13
Current: $10.59
Upside: +22.76%
Puma Biotechnology
Mar 1, 2019
Maintains: Buy
Price Target: n/a
Current: $5.02
Upside: -